Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 9/20 | 1.00 |
| ▸ | PSEN1 | P49768 | 5/20 | 0.74 |
| ▸ | PSEN2 | P49810 | 5/20 | 0.74 |
| ▸ | APH1B | Q8WW43 | 5/20 | 0.74 |
| ▸ | NCSTN | Q92542 | 5/20 | 0.74 |
| ▸ | APH1A | Q96BI3 | 5/20 | 0.74 |
| ▸ | PSENEN | Q9NZ42 | 5/20 | 0.74 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.64 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.63 |
| ▸ | EGFR | P00533 | 1/20 | 0.61 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3755282 | 1.00 | LRRK2 (1.00) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5475460 | 1.00 | LRRK2 (1.00) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5477805 | 0.91 | LRRK2 (0.83) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5477806 | 0.91 | LRRK2 (0.83) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1021458 | 0.88 | LRRK2 (0.78) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2132052 | 0.88 | LRRK2 (0.78) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1021460 | 0.88 | LRRK2 (0.78) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL14674660 | 0.85 | LRRK2 (0.75) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5474728 | 0.85 | LRRK2 (0.75) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3804991 | 0.85 | LRRK2 (0.75) | LRRK2PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130035364-A1 | BENZYLIDENE-INDOLINONE COMPOUNDS AND THEIR MEDICAL USE | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2013-02-07 | — | — | US | claimed |
| US-20090264494-A1 | USE OF NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-10-22 | — | — | US | claimed |
| US-20070167488-A1 | Novel therapeutic use | LEO PHARMA A/S (DK) | 2007-07-19 | — | — | US | claimed |
| EP-1696906-A1 | NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES | Leo Pharma A/S (DK) | 2006-09-06 | — | — | EP | claimed |
| WO-2005058309-A1 | NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES | LEO PHARMA A/S (DK) | 2005-06-30 | — | — | WO | claimed |
| US-8877946-B2 | Benzylidene-indolinone compounds and their medical use | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2014-11-04 | — | — | US | disclosed |
| US-8877946-B2 | Benzylidene-indolinone compounds and their medical use | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2014-11-04 | — | — | US | disclosed |
| US-20130035364-A1 | BENZYLIDENE-INDOLINONE COMPOUNDS AND THEIR MEDICAL USE | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2013-02-07 | — | — | US | disclosed |
| US-20130035364-A1 | BENZYLIDENE-INDOLINONE COMPOUNDS AND THEIR MEDICAL USE | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2013-02-07 | — | — | US | disclosed |
| US-20100298376-A1 | USE OF NOVEL NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-11-25 | — | — | US | disclosed |
| US-20090264494-A1 | USE OF NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-10-22 | — | — | US | disclosed |
| US-20070167488-A1 | Novel therapeutic use | LEO PHARMA A/S (DK) | 2007-07-19 | — | — | US | disclosed |
| EP-1696906-A1 | NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES | Leo Pharma A/S (DK) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005058309-A1 | NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES | LEO PHARMA A/S (DK) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298376-A1 | USE OF NOVEL NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS | NLN, HTT, PARK7 | LRRK2 39/4885PSEN1 18/4885PSEN2 9/4885 |
| US-20130035364-A1 | BENZYLIDENE-INDOLINONE COMPOUNDS AND THEIR MEDICAL USE | ERBB2, ABL1, IGF1R | LRRK2 19/4885PSEN1 3380/4885PSEN2 3088/4885 |
| US-20070167488-A1 | Novel therapeutic use | MAG, PMP22, MYT1 | LRRK2 1753/4885PSEN1 1618/4885PSEN2 822/4885 |
| US-20090264494-A1 | USE OF NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS | NLN, BDNF, HTT | LRRK2 26/4885PSEN1 15/4885PSEN2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.